A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Trial Profile

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Durvalumab (Primary) ; Mocetinostat (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 13 Nov 2017 According to a Mirati Therapeutics media release, phase 2 data from the combination of mocetinostat and durvalumab in patients with checkpoint refractory NSCLC are expected in the first quarter of 2018.
    • 12 Oct 2017 According to a Mirati Therapeutics media release, Stage 1 of the study is currently enrolling nine patients in each cohort; one cohort has already met the prespecified criteria for expansion into stage 2 with at least one confirmed partial response. Mirati will provide an update on this study by the end of the year.
    • 29 Aug 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top